THIENOPYRIMIDINES WITH INHIBITORY EFFECT WITH RESPECT TO PHOSPHODIESTERASE V (PDE V), METHOD OF THEIR SYNTHESIS AND PHARMACEUTICAL COMPOSITION Russian patent published in 2003 - IPC

FIELD: organic chemistry, biochemistry, medicine, pharmacy. SUBSTANCE: invention relates to novel thienopyrimidines and their physiologically acceptable salts with inhibitory effect with respect to phosphodiesterase V (PDE V) that can be used for control of cardiovascular system diseases and for treatment and/or therapy of potency disorder. Invention relates also to method of their synthesis and pharmaceutical composition based on thereof. New compounds correspond to the general formula (I) where each of R¹, R² means independently each of other A or Hal; or R¹, R² mean in common alkylene with 3-5 C-atoms; each of R³, R⁴ means independently each of other H, A, OA or Hal; R³ and R⁴ form in common also -O-CH₂-CH₂-, -O-CH₂-O- or -O-CH₂-CH₂-O-; A means alkyl with 1-6 carbon atoms; X means 5-7-membered saturated heterocyclic ring mono- or disubstituted with residue R⁵, or 5-7-membered unsaturated or saturated isocyclic ring mono- or disubstituted with residue R⁵; R⁵ means COOH, CH₂COOH or CH₂CH₂COOH; Hal means F, Cl, Br or J and n = 0, 1, 2 or 3. Invention relates also to method of synthesis of compounds of the formula (I) or their physiologically acceptable salts where X means saturated 5-7- membered heterocyclic ring mono- or disubstituted with residue R⁵ and bound through N atom. Method involves interaction of compound of the formula (II) where R¹, R², R³, R⁴ and n have values indicated above and L means Cl, Br, OH, SCH₃ or reactive esterified OH-group with saturated 5-7-membered heterocyclic ring mono- or disubstituted with residue R⁵ where R⁵ means value indicated above. In synthesized compound of the formula (I) one residue of R³, R⁴ and/or X is transformed to other residue R³, R⁴ and/or X by saponification of ester group and/or acid compound of the formula (I) is converted to its salt by treatment with a base. Pharmaceutical composition comprises at least one compound of the formula (I) by claim 1 and/or one of its physiologically acceptable salts. Strength of inhibitory effect of compound of the formula (I) on PDE V activity exceeds effect the known structural related compounds by 10-1000 times. EFFECT: improved method of synthesis, valuable medicinal and biochemical properties of compounds. 6 cl, 1 tbl, 20 ex